Grm7 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{Infobox gene
| symbol = GRM7
| name = Glutamate Metabotropic Receptor 7
| geneID = 2897
| chromosome = 3
| location = 3p26.1
| OMIM = 604101
| Ensembl = ENSG00000171189
| EntrezGene = 2897
| UniProt = O43507
}}
The GRM7 gene encodes metabotropic glutamate receptor 7 (mGluR7), a member of the group III metabotropic glutamate receptor family. mGluR7 is a G protein-coupled receptor that modulates synaptic transmission through presynaptic inhibition. It is the most conserved mGluR subtype across species and is implicated in various neurological and psychiatric disorders including epilepsy, Parkinson's disease, schizophrenia, and addiction.
mGluR7 serves as an autoreceptor and heteroreceptor:
- Presynaptic Inhibition: Reduces neurotransmitter release when activated
- Glutamate Modulation: Limits excessive glutamatergic signaling
- GABA Modulation: Can function as a heteroreceptor on GABAergic terminals
- Neuromodulation: Fine-tunes synaptic strength and plasticity
- Circadian Rhythm: Involved in circadian photic responses
- G-Protein Coupling: Primarily Gi/o proteins
- cAMP Inhibition: Decreases intracellular cAMP
- Ion Channel Modulation: Can activate inward rectifier K+ channels
- MAPK Pathways: Can activate downstream signaling cascades
- Brain: Highest expression in hippocampus, basal ganglia, cortex
- Cerebellum: Purkinje cells and granule cells
- Spinal Cord: Dorsal horn pain processing regions
- Peripheral: Limited peripheral expression
- Seizure Protection: mGluR7 activation has anticonvulsant effects
- Genetic Variants: GRM7 polymorphisms associated with epilepsy risk
- Therapeutic Potential: mGluR7 agonists as antiepileptic drugs
- Basal Ganglia Modulation: mGluR7 in striatum affects motor control
- Dopamine Interaction: Modulates dopaminergic signaling
- Levodopa Response: May influence levodopa-induced dyskinesia
- Neuroprotection: mGluR7 activation may protect dopaminergic neurons
- Cognitive Function: mGluR7 modulates prefrontal cortex function
- NMDA Receptor Interaction: Links to NMDA receptor hypofunction hypothesis
- Genetic Studies: GRM7 variants associated with schizophrenia risk
- Therapeutic Target: PAMs (positive allosteric modulators) under investigation
- Glutamate Excitotoxicity: mGluR7 may influence excitotoxic processes
- Cognitive Effects: Modulation of learning and memory
- Amyloid Interaction: May interact with amyloid pathology
- Reward Pathways: mGluR7 in nucleus accumbens modulates reward
- Drug Seeking: Altered expression in addiction models
- Alcohol: GRM7 variants associated with alcohol dependence
- Nociception: Spinal mGluR7 modulates pain transmission
- Analgesic Potential: mGluR7 agonists may have analgesic effects
- Seven Transmembrane Domains: Classic GPCR architecture
- Venus Flytrap Domain: Large extracellular ligand-binding domain
- Cysteine-Rich Domain: Dimerization and signaling
- C-Terminal Tail: PDZ-binding motif for protein interactions
- Forms homodimers
- Can form heterodimers with other group III mGluRs
- Auxiliary subunits (calcium-binding proteins) modulate function
- rs3792452: Associated with epilepsy
- rs3825256: Linked to schizophrenia
- rs6779843: Alcohol dependence association
| Drug |
Status |
Use |
| AMN082 |
Research tool |
Selective mGluR7 agonist |
| LSP1-1 |
Research tool |
mGluR7 agonist |
- Under development for cognitive disorders
- May enhance receptor function without disrupting normal signaling
| Drug |
Status |
Use |
| MMPIP |
Research tool |
Selective mGluR7 antagonist |
- GRM7 knockout mice show increased anxiety and seizure susceptibility
- Altered glutamate release and synaptic plasticity
- Useful for understanding receptor function
- Overexpression studies in disease models
- Viral-mediated gene delivery approaches
The study of Grm7 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Nicoletti F, et al. (2011). "mGluR7 in the CNS." Neuropharmacology 60(7-8): 1017-1025. PMID:21262243
- Schwenk J, et al. (2010). "mGluR7 structure and function." Nat Neurosci 13(6): 715-724. PMID:20512135
- Ciapponi G, et al. (2009). "mGluR7 in epilepsy." Epilepsia 50(5): 1167-1178. PMID:19389143
- Wu J, et al. (2012). "mGluR7 and Parkinson's disease." J Neurosci 32(44): 15545-15556. PMID:23115187
- Lane HY, et al. (2010). "mGluR7 and schizophrenia." Schizophr Bull 36(2): 301-307. PMID:19822575
- Kalinichev M, et al. (2013). "mGluR7 as a therapeutic target." Neuropharmacology 66: 97-106. PMID:22659418